市场调查报告书
商品编码
1447723
抽吸针市场评估:按应用、治疗、最终用户和地区划分的机会和预测(2017-2031)Aspiration Needles Market Assessment, By Application, By Procedure, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球抽吸针市场规模预计将从2023年的9.275亿美元成长到2031年的15.4272亿美元,2024-2031年预测期间复合年增长率为6.57%,预计规模将会成长。
由于全球癌症盛行率不断上升,抽吸针市场预计将成长。 随着癌症患者数量的增加,用于活检和其他诊断的抽吸针的需求预计将显着增加。 各国政府和医疗机构正在推动癌症筛检和诊断,导致活检针的需求增加。 此外,人们越来越喜欢侵入性较小的诊断方法,这推动了对抽吸针的需求。 此外,快速的技术进步也是主要的成长动力。 创新技术正在提高活检程序的准确性和效率,从而改善患者的治疗效果和更高的采用率,进一步推动市场成长。 然而,与使用抽吸针相关的设计风险和併发症是该市场的主要挑战。 进入者专注于产品创新和合作伙伴关係,以克服这些挑战并增加利润。
癌症病人增加
癌症是全世界死亡的主要原因。 生活方式的改变、烟酒消费以及辐射暴露是癌症的主要原因,导致癌症病例显着增加。 癌症早期检测诊断方法的进步正在迅速增加癌症诊断市场的需求。 大多数癌症病例是透过活检方法诊断的,其中广泛使用抽吸针。 癌症活检对于降低死亡率至关重要,这正在推动全球抽吸针市场的扩张。
世界卫生组织 (WHO) 报告称,2020 年新增癌症病例约为 1,930 万例,预计到 2025 年这一数字将增至 2,160 万例。 乳癌是全世界最常见的癌症,过去五年估计有 780 万名女性死于乳癌。 根据 Globocan 最近的调查数据,乳癌约占所有癌症病例的 12%。 这种常见疾病可能会在未来几年推动市场的显着成长。
对微创诊断的偏好日益增加
人们对微创诊断程序的日益青睐正在推动对抽吸针的需求,以降低发病率、死亡率、住院时间和成本。 微创手术,例如由影像技术引导的手术,允许医生透过针刺或导管治疗症状,从而减少开放手术的需要。 这些手术越来越多地被用作一种治疗方式,改善患者的治疗效果,并为不适合传统开放性手术的患者提供更多的治疗选择。 2023 年 10 月,Praxis Medical 的 EndoCore 经支气管针吸活检 (EBUS-TBNA) 微针活检技术获得 FDA 510(k) 许可。 EndoCore EBUS-TBNA活检装置由美国一家医疗器材公司开发,用于辅助肺癌的诊断和分期。
在癌症应用的优势
细针穿刺切片(FNA)广泛应用于乳癌、肺癌、大肠癌、摄护腺癌、肾癌、骨及骨髓癌等的诊断。 FNA 被认为是一种优秀、安全且具有成本效益的诊断方法,特别是在乳房肿块的评估方面。 此外,FNA 非常准确,对某些类型的癌症的敏感性超过 90%,特异性超过 95%。 公司正在积极致力于开发解决方案并获得监管部门的批准。
本报告调查了全球抽吸针市场,提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。
Global aspiration needles market is projected to witness a CAGR of 6.57% during the forecast period 2024-2031, growing from USD 927.5 million in 2023 to USD 1542.72 million in 2031. The aspiration needle market is anticipated to thrive due to the growing prevalence of cancer across the globe. With the growing number of cancer cases, the demand for aspiration needles for biopsy and other diagnostics is expected to increase significantly. Governments and health organizations promote cancer screenings and diagnostics, contributing to an increase in demand for biopsy needles. There is a growing preference for minimally invasive diagnostic procedures, which drives demand for aspiration needles. Moreover, rapid technological advancements represent a significant growth-inducing factor. Innovative technologies enable better accuracy and efficiency in biopsy procedures, leading to improved patient outcomes and increased adoption rates, further boosting the market growth. However, risks associated with the use of aspiration needles and design complications are some major challenges for this market. Market players are focusing on product innovations and partnerships to overcome these challenges and drive profits.
In September 2023, Broncus Medical launched the BioStar Transbronchial Aspiration Needle (TBNA) to facilitate minimally invasive diagnostic procedures. This advanced needle enables medical professionals to collect precise tissue samples and high-quality specimens, aiding in the diagnosis and staging of lung cancer. The needle seamlessly integrates with endobronchial ultrasound bronchoscopy (EBUS) techniques, enhancing clinical outcomes and patient care. Designed for versatility, the BioStar TBNA is suitable for both conventional TBNA (cTBNA) and EBUS-TBNA diagnostic methods. Broncus offers the needle in 21G, 22G, and 25G sizes to accommodate various clinical needs.
Increasing Number of Cancer Cases
Cancer is a primary cause of death worldwide. Changes in lifestyle, tobacco and alcohol consumption, and radiation exposure are leading causes of cancer and have resulted in a significant increase in cancer cases. Advancements in diagnostics for early cancer detection have surged the demand in the cancer diagnostics market. The majority of cancer cases are diagnosed through the biopsy method and aspiration needles are widely used for that purpose. Cancer biopsy is essential to lower mortality rates, thereby driving the global aspiration needle market's expansion.
The World Health Organization reported approximately 19.3 million new cancer cases in 2020, a number that is projected to rise to 21.6 million by 2025. Breast cancer is the most common cancer globally, with an estimated 7.8 million women surviving breast cancer in the past five years. Data from recent Globocan study indicates that breast cancer accounts for roughly 12% of all cancer cases. This prevalent condition is likely to drive significant market growth over the forthcoming years.
Growing Preference for Minimally Invasive Diagnostic Procedures
The growing preference for minimally invasive diagnostic procedures is driving the demand for aspiration needles due to the benefits they offer in terms of decreased morbidity, mortality, hospitalization time, and expenses. Minimally invasive procedures, such as those guided by imaging technologies, allow physicians to treat conditions through needle punctures or catheters, reducing the need for open surgeries. These procedures are increasingly being used in therapeutic modalities, leading to improved patient outcomes, and expanded treatment options for individuals who are not candidates for traditional open surgeries. Manufacturers are actively involved in product development to cater to the market needs. For example, in October 2023, Praxis Medical received FDA 510(k) clearance for its EndoCore Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) tiny needle biopsy technology. The EndoCore EBUS-TBNA biopsy instrument was created by an American medical device business to aid in the diagnosis and staging of lung cancer.
Dominance of Cancer Application
Fine-needle aspiration (FNA) is widely used in the diagnosis of breast cancer, lung cancer, and other types of cancer, such as colorectal, prostate, kidney, and bone and bone marrow cancer. FNA is considered an excellent, safe, and cost-effective diagnostic procedure, particularly for evaluating breast lumps. Additionally, FNA is highly accurate, with sensitivities above 90% and specificities above 95% for certain types of cancer. Market players are actively involved in developing solutions and obtaining regulatory clearance. For instance, in September 2023, Limaca Medical obtained approval from the FDA for its innovative Precision GI, a first-of-its-kind endoscopic biopsy tool for gastrointestinal diseases. Unlike other existing biopsy devices, Precision GI uses an automated, motorized cutting needle, ensuring precise tissue collection for accurate diagnosis. Limaca Medical, a leading healthcare company, is committed to revolutionizing endoscopic biopsy procedures for patients battling life-threatening digestive and lung cancers.
Image-guided Systems Dominate the Market
Image-guided systems are preferred for aspiration needle biopsies due to their higher accuracy compared to palpation-guided biopsies. Research shows that image-guided biopsies have a sensitivity of 96.3% for diagnosing malignant lesions, while palpation-guided biopsies have a lower sensitivity of 46.7%. Image guidance, such as ultrasound, allows for real-time visualization of the needle placement, ensuring accurate sampling of the target tissue. Additionally, image-guided biopsies offer advantages like better patient tolerance, improved cosmetic outcomes, and cost-effectiveness compared to open surgical biopsies. The use of image guidance in needle biopsies improves diagnostic accuracy and minimizes the risk of erroneous sampling, making it the preferred choice for various medical procedures.
In February 2023, TransMed7, a company specializing in breast biopsy devices, announced the clinical use of production models of its Concorde US ultrasound-guided biopsy devices. The Concorde US platform consists of two models, the Concorde US model and Concorde ST. Among these, Concorde US can be used handheld with ultrasound guidance or with an optional stage mount adapter for stereotactic and 2D/3D tomosynthesis procedures. On the other hand, Concorde ST is suitable for stereotactic and 2D/3D tomosynthesis-guided breast biopsy procedures, offering console-replacing functionality.
North America to be the Dominating Region
North America dominates the aspiration needle market due to several reasons. Firstly, there is a well-developed healthcare infrastructure in the region, which supports the adoption of advanced medical technologies such as aspiration needles. Secondly, there is high healthcare spending in countries like the United States, which drives the demand for innovative medical devices. Thirdly, there is an increasing prevalence of chronic diseases, which require regular monitoring and treatment using aspiration needles. Finally, there is a strong focus on improving the visibility of biopsy needles to aid market growth, which contributes to the dominant position of North America in the aspiration needle market.
Future Market Scenario
Over time, transthoracic needle aspiration (TTNA) has undergone major advancements, and continuing developments promise to improve its efficiency and introduce individualized medicine. Technology advancements, better biopsy samples, and increased capabilities are among these advancements. TTNA has moved from fluoroscopy to computed tomography (CT), resulting in better visualization and cutting-edge biopsy equipment. In TTNA operations, a variety of needles are utilized, including suction needles, cutting needles, and automated core biopsy needles. The future holds promising growth for the aspiration needles market.
Key Players Landscape and Outlook
Merit Medical Systems, Cook Group Incorporated, Olympus Corporation, Medtronic PLC, Argon Medical Devices Inc., and Boston Scientific Corporation are some of the key players in the aspiration needles market. These companies are major players in the industry, focusing on strategies like product launches, technological innovations, and partnerships to strengthen their market position. Market tactics like mergers and acquisitions are some other factors driving the market growth.
In November 2023, Broncus, through its Chinese subsidiary, agreed to purchase 100% of Hangzhou Jingliang, a Chinese device manufacturer. This acquisition aims to expand Broncus's offerings in lung disease diagnosis and treatment, including the BioStar transbronchial aspiration needle (TBNA) for minimally invasive diagnostic applications. China represents a significant market for Broncus, contributing USD 4.25 million in revenue during the first half of the fiscal year 2023.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.